A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 Post author: Post published:April 20, 2026 Post category: Continue ReadingA Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors Post author: Post published:April 20, 2026 Post category: Continue ReadingA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL Post author: Post published:April 20, 2026 Post category: Continue ReadingBAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Post author: Post published:April 20, 2026 Post category: Continue ReadingAllogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study Post author: Post published:April 20, 2026 Post category: Continue ReadingGeriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS Post author: Post published:April 20, 2026 Post category: Continue ReadingCMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingIntracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Post author: Post published:April 20, 2026 Post category: Continue ReadingStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
